Palynziq (pegvaliase-pqpzl) for phenylketonuria (PKU)
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.63 alerts
Get alerted when Policy 05.02.63 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage policy for use of Palynziq in adults with phenylketonuria (PKU); describes initial and continuation medical necessity criteria, documentation and prescribing requirements, quantity limits, and dosing guidance for providers and prior authorization reviewers.
FDA label expansion increasing the maximum allowable dose for Palynziq to 60 mg was incorporated.
Safety concerns and REMS requirements for anaphylaxis with Palynziq emphasized, including requirement to prescribe auto-injectable epinephrine and certification/enrollment in the REMS.
Coverage Criteria for Palynziq (pegvaliase-pqpzl)
inv-01: Initial Approval
Covered when ALL of the following are met:
From Criteria for Initial Approval.
inv-02: Continuation of Therapy — clinical response
Covered when ALL of the following are met:
From Continuation of Therapy criteria.
inv-03: Continuation of Therapy — nonresponse or still titrating
Covered when ALL of the following are met (alternative pathway):
Allows limited continuation while titrating or assessing response; approval length = 6 months when titrating.
inv-04: Evidence summary — efficacy, neuropsychiatric outcomes, and safety
Evidence-based findings from PRISM trials that should inform coverage determinations:
Supports coverage when target Phe reductions expected.
Supportive but limited evidence of neuropsychiatric benefit.
Coverage should require REMS compliance, epinephrine prescription, and monitoring plans.
Palynziq (pegvaliase-pqpz) is considered not medically necessary for members who do not meet the coverage criteria outlined in this policy. Members who are currently receiving Palynziq as samples or through the manufacturer’s patient assistance program must still meet the initial approval criteria to qualify for coverage, ensuring consistent application of policy requirements regardless of how the medication was initially obtained.
In the PRISM‑2 randomized discontinuation (part 2), patients who were stable on pegvaliase and entered the randomized discontinuation did not demonstrate a decline in neuropsychiatric or neurocognitive symptoms as a result of discontinuation. Although blood phenylalanine levels rose in placebo groups while pooled pegvaliase-treated patients remained below guideline/FDA thresholds (<600 μmol/L), no neuropsychiatric benefit from continued therapy was observed in this randomized discontinuation analysis.
Use of Palynziq is not medically necessary for any member who does not meet the specific criteria set forth in this policy. Coverage decisions require documentation showing that the member satisfies the initial and continuation criteria described in the policy prior to approval.
The document does not list additional explicit not‑medically‑necessary (NMN) conditions beyond the general statement that members failing to meet policy criteria are NMN. Clinical trial data provide mixed signals on neuropsychiatric outcomes: secondary measures (ADHD RS‑IV IA, POMS, PKU‑POMS) showed mean score improvements at 12 and 24 months, and PRISM‑2 found durable Phe control with continued pegvaliase, but the randomized discontinuation did not show neuropsychiatric declines after discontinuation. Given these limitations, the policy does not define further NMN stopping rules based solely on neuropsychiatric outcome evidence.
Coding, Dosing Thresholds, and Dose Limits
| unspecified | Policy references use of appropriate CPT, HCPCS, revenue, and ICD diagnostic codes but does not list specific codes in this section. |
Prior Authorization, REMS, Dosing, and Documentation Requirements
Prior authorization required — specialist and criteria verification
Prior authorization is required and must include documentation listed in the Required Documentation section and that the prescriber is a metabolic disease/PKU specialist or consulted with one; initial approval criteria (diagnosis of PKU, age ≥18, baseline Phe >600 μmol/L despite management, prior sapropterin inadequate/intolerant/contraindicated, not used concurrently with sapropterin/Sephience, and prescription for auto-injectable epinephrine) must be met.
- Prescriber must be a metabolic disease/PKU specialist or in consultation with one.
- Initial approval requires meeting all criteria listed under Criteria for Initial Approval.
Prior authorization — dosing limit and REMS confirmation
Prior authorization documentation must reflect allowance for dosing up to 60 mg once daily (FDA label expansion) and include prior dose trials and response; confirm REMS enrollment/certification and that auto-injectable epinephrine was prescribed.
- Document prior dose trials and response, including if patient escalated to 60 mg.
- Confirm prescriber, patient, and dispensing pharmacy REMS enrollment; document epinephrine prescription.
Step therapy — sapropterin trial or documented contraindication required
Before initiating Palynziq, submit documentation that the member had an inadequate response, intolerance, or a clinical reason to avoid a sapropterin product (step therapy requirement).
- Evidence of inadequate response or intolerance to sapropterin, or documented clinical rationale to avoid sapropterin, must be in the medical record.
- This requirement is part of the Criteria for Initial Approval.
Dose titration — slow uptitration with possible escalation to 60 mg
Start at lower doses with planned incremental uptitration; some patients may require escalation to 60 mg once daily to achieve response per PRISM studies, and many who first respond at 60 mg did so within 16 weeks.
- Titrate slowly to allow immune stabilization and monitor for hypersensitivity/anaphylaxis.
- If not at clinical response and not yet titrated to 60 mg or completed 16 weeks at max dose, approval may be allowed while titrating (approval = 6 months).
Required documentation — baseline Phe, treatment response, and concomitant therapy
Submit medical records/chart notes and laboratory values showing baseline blood phenylalanine > 600 μmol/L despite a phenylalanine‑restricted diet and sapropterin, documentation of response per continuation criteria (blood Phe values), and documentation that Palynziq will not be used concurrently with sapropterin or Sephience (or will be discontinued after overlap).
- Baseline and follow-up blood Phe laboratory values must be included.
- Records must show discontinuation plan if overlap with sapropterin or confirmation that concurrent use will not occur.
REMS enrollment and epinephrine prescription must be documented
Document REMS enrollment/certification for prescriber, patient, and dispensing pharmacy; document that auto‑injectable epinephrine was prescribed and that the patient was counseled on recognition and response to anaphylaxis.
- REMS certification/enrollment forms or confirmation must be provided.
- Record of prescription for auto‑injectable epinephrine and documentation of patient counseling on anaphylaxis are required.
Denial risk — not meeting criteria or receiving samples without meeting criteria
Therapy is considered not medically necessary for members who do not meet the stated criteria; members receiving samples or manufacturer patient assistance must still meet initial approval criteria to be eligible for coverage.
- Members not meeting Criteria for Initial Approval are not eligible for coverage.
- Patients receiving samples or assistance must meet the same initial approval criteria.
Denial risk — missing REMS/epinephrine/counseling documentation
Failure to document REMS enrollment/certification, absence of a prescription for auto‑injectable epinephrine, or inability to confirm patient counseling on anaphylaxis recognition/response may result in coverage denial or dispensing restriction.
- REMS documentation and epinephrine prescription are mandatory per REMS requirements.
- Lack of documentation of patient counseling on anaphylaxis is a coverage risk.
Definitions and Background Related to Palynziq Use
Phenylketonuria (PKU) is an inherited metabolic disorder caused by deficiency of phenylalanine metabolism, resulting in elevated blood phenylalanine (Phe) with potential neurocognitive and psychiatric consequences. Lifelong management is recommended, and guideline targets (ACMG) typically aim for Phe in the range of 120–360 μmol/L. Palynziq (pegvaliase) is an enzyme substitution biologic indicated to reduce blood Phe concentrations in adults with PKU who have uncontrolled blood Phe despite existing management.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.